Cold Spring Harbor Laboratory (SCHL) and Northwell Health have extended a strategic affiliation that aims to provide cancer patients with greater access to personalized healthcare. The alliance is extended for another 10 years.
The affiliation is designed to bring the latest “biology research to the bedside of tens of thousands of cancer patients in diverse communities across the state,” according to a news release about the extended alliance.
“The alliance between Cold Spring Harbor Laboratory and Northwell Health brings transformative bioscience research into the clinic,” CSHL President and CEO Bruce Stillman said in a news release.
Stillman added that “Northwell Health serves a remarkably diverse patient population. This agreement will provide patient communities with greater access to cutting-edge biomedical technology, allowing for more precise diagnoses and treatments, and ultimately facilitating new breakthroughs in cancer care.”
“Reaffirming our exclusive strategic affiliation with Cold Spring Harbor Laboratory and Northwell Health marks a pivotal moment in accelerating our efforts to advance cancer research and revolutionize treatment in the fight against cancer,” Dowling, president and CEO of Northwell Health, said in the news release.
“We are building on nearly 10 years of shared vision and collaboration, merging cutting-edge discovery science with novel clinical trials to drive therapeutic applications for the patients we serve across the New York metropolitan area and beyond,” Dowling added.
The CSHL-Northwell Health affiliation is designed to enhance biology and cancer research at CSHL’s NCI-designated Cancer Center and more than 60 research labs, as well as the Feinstein Institutes for Medical Research, the research arm of Northwell Health, with 50 research labs and 5,000 researchers and staff across the system.
The affiliation also aims to translate basic research into clinical applications, provide access to diverse patient populations, and train the next generation of scientist-clinicians. Over the past 10 years, the affiliation has funded 82 research projects, resulting in more than 100 peer-reviewed publications. Through this integration, CSHL appointed 13 adjunct professors and trained 24 medical students, 27 residents and fellows. Together, they’ve initiated three clinical trials in various stages.
One of the affiliation’s collaborations includes the development of more than 200 cancer organoid models through its organoid facility on Long Island. These living three-dimensional tissue models are derived from patient tumor cells and cultivated outside the body, in a clinical laboratory, for disease analysis and drug testing. This technology in Phase-II clinical trials enables clinicians to predict favorable patient responses to new drug combinations.
The CSHL-Northwell Health affiliation has also led to discoveries in pancreatic cancer, leukemia, glioblastoma and COVID-19 research.
Northwell Health and the Northwell Health Cancer Institute, comprising 400 physicians and researchers, have expanded their oncology footprint since the initial CSHL affiliation was announced in 2015. The Northwell Health Cancer Institute, in the last three years, invested nearly $550 million to open and expand cancer treatment centers throughout Long Island and New York City. Initiatives include the $32 million, 37,000-square-foot outpatient Northwell Cancer Institute at Rego Park, and the $43 million, 40,000-square-foot Florina Cancer Center in Staten Island, which provides adult and pediatric care.
Northwell is also building a new 200,000-square-foot medical pavilion adjacent to its Lenox Hill Hospital in Manhattan, which will be anchored by a cancer center. Northwell said it treats more than 19,000 people with cancer through its integrated health system and nine cancer centers.
Copyright © 2024 BridgeTower Media. All Rights Reserved.
Most Popular
Comments / 0